Global Information
회사소개 | 문의 | 비교리스트

길랭 바레 증후군 : 파이프라인 리뷰

Guillain-Barre Syndrome - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 332891
페이지 정보 영문 62 Pages
가격
US $ 2,000 ₩ 2,410,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,820,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,230,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


길랭 바레 증후군 : 파이프라인 리뷰 Guillain-Barre Syndrome - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 62 Pages

길랭 바레 증후군(GBS)이란 체내 면역 시스템이 말초신경계의 일부를 공격하므로 처음에 정도의 차이는 있으나 다리의 근력 저하 및 쿡쿡 찌르는 감각이 나타납니다. 많은 경우, 팔 및 상반신에 좌우 대칭적인 근력 저하 및 감각 이상이 확대됩니다. 이와 같은 증상은 특정 근육이 전혀 움직이지 못하게 될 때까지 계속되며, 심할 경우, 거의 전신이 마비되기도 합니다. 위험인자로 인플루엔자 바이러스, 미코플라스마 폐렴, 호지킨 림프종, 엡스타인 바 바이러스 등을 들 수 있습니다.

세계의 길랭 바레 증후군(Guillain-Barre Syndrome) 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요(제품 개요, 기능 메커니즘, 연구 개발 진전 상황), 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위
  • 길랭 바레 증후군 개요

치료제 개발

  • 파이프라인 제품 : 길랭 바레 증후군 - 개요
  • 기업에서 개발중인 치료제
  • 대학/기관에서 연구중인 치료제
  • 기업에서 개발중인 제품
  • 대학/기관에서 연구중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Akari Therapeutics Plc
  • Annexon Inc
  • CuraVac Inc
  • Hansa Medical AB
  • Regenesance BV
  • Vitality Biopharma Inc

약제 개요

휴지중인 프로젝트

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 17.05.19

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Guillain-Barre Syndrome, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Guillain-Barre Syndrome - Pipeline by Akari Therapeutics Plc, H1 2020
  • Guillain-Barre Syndrome - Pipeline by Annexon Inc, H1 2020
  • Guillain-Barre Syndrome - Pipeline by Cellenkos Inc, H1 2020
  • Guillain-Barre Syndrome - Pipeline by Complement Pharma BV, H1 2020
  • Guillain-Barre Syndrome - Pipeline by CuraVac Inc, H1 2020
  • Guillain-Barre Syndrome - Pipeline by Hansa Biopharma AB, H1 2020
  • Guillain-Barre Syndrome - Pipeline by Vitality Biopharma Inc, H1 2020
  • Guillain-Barre Syndrome - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Guillain-Barre Syndrome, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2020, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.

Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk Factors include influenza virus, mycoplasma pneumonia, Hodgkin's lymphoma and Epstein-Barr virus.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 2, 1 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Guillain-Barre Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Guillain-Barre Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Guillain-Barre Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Guillain-Barre Syndrome - Overview
    • Guillain-Barre Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Guillain-Barre Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Guillain-Barre Syndrome - Companies Involved in Therapeutics Development
    • Akari Therapeutics Plc
    • Annexon Inc
    • Cellenkos Inc
    • Complement Pharma BV
    • CuraVac Inc
    • Hansa Biopharma AB
    • Vitality Biopharma Inc
  • Guillain-Barre Syndrome - Drug Profiles
    • ANX-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CK-0801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CP-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imlifidase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nomacopan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Guillain-Barre Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Guillain-Barre Syndrome - Dormant Projects
  • Guillain-Barre Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Apr 15, 2019: Hansa Biopharma receives ethics and regulatory clearance to start Phase 2 study of imlifidase in Guillain Barre Syndrome
      • Feb 16, 2018: Hansa Medical receives FDA Orphan Drug Designation for IdeS and the treatment of Guillain-Barre syndrome
      • Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome
      • May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barre Syndrome
      • May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barre Syndrome
      • Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
      • Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
      • Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q